San Francisco Professional Events List


Novel Cardiovascular Therapeutics Summit


Date
Feb 28, 2017 - 08:00 AM - Mar 01, 05:15 PM
Link to Website
Organizer
Hanson Wade
Venue
Hotel Kabuki
Location
1625, Post St

San Francisco,
CA,
USA,
ZIP: 94115
Phone: 415-922-3200

The Novel Cardiovascular Therapeutics Summit 2017 is a unique meeting dedicated to translating the latest developments in the genomic and molecular understanding of the causes of cardiovascular disease, heart failure and cardiomyopathy into new pharmacological therapies in the clinic.

With an agenda driven by scientific sessions, case studies and clinical data, this meeting will address your major challenges in preclinical and clinical cardiovascular research to achieve safer, faster and more cost-effective cardiovascular drug development.

Join the conversation with fellow academics, researchers and biopharmaceutical industry leaders at the forefront of cardiovascular drug development in a collaborative effort to drive translational research in this field forward.



Agenda


Day One 
Tuesday, February 28, 2017

08.00 Registration

08.50 Co-Chairs’ Opening Remarks

  • Kenneth W. MahaffeyM.D., Professor of Medicine; Vice Chair of Clinical Research; Director, Stanford Center for Clinical Research (SCCR), Stanford University
  • Scott M. WassermanM.D., FACC, VP, Global Development, Cardiovascular & Metabolic Therapeutic Area Head, Head of Development Design Center, Amgen Inc.

Synopsis

  • Outlining the state of the state in cardiovascular therapeutic development – recent developments

 

Novel Pathways That Intersect Between CVD, Diabetes & Diabetic Kidney Disease

09.00 SGLT2 Inhibitors: Cardiorenal Protection & Possible Mechanisms

  • Mark C. KowalaPh.D, CSO, CardioMetabolic and Diabetic Complications Drug Hunting Team, Eli Lilly and Company

Synopsis

  • Understanding the potential mechanism of action of SGLT2 inhibitors in cardiovascular risk reduction
  • Exploring the possibilities of cardiometabolic therapeutic approaches

09.30 Is Metformin a Cardiovascular Drug? – An Overview

  • Gregory SchwartzM.D., Ph.D, Professor of Medicine (Cardiology), University of Colorado, Denver

Synopsis

  • Analyzing the clinical evidence supporting a possible cardiovascular benefit of metformin
  • Evaluating the experimental evidence supporting a possible cardiovascular benefit of metformin
  • Designing a clinical trial to test the hypothesis that metformin reduces ischemic cardiovascular events

10.00 Morning Refreshments & Speed Networking

11.00 An Update on the Current Status of PCSK9 Inhibitor Development

  • Jay EdelbergM.D., Ph.D, VP & Head, Cardiovascular Development, Sanofi

Synopsis

  • Briefly outlining the history of discovery and development to date
  • Exploring the key details of the latest outcomes trial

11.30 ZD100: A Novel Designer Particulate Guanylyl Cyclase Receptor-An Activating Peptide for Cardiometabolic Disease

  • John C. Burnett JrM.D., Marriott Family Professor of Cardiovascular Research, Division Of Cardiovascular Diseases, Mayo Clinic

Synopsis

  • Exploring how the natriuretic peptide/pGC-A/cGMP pathway represents an unprecedented opportunity to mediate cardiorenal and metabolic protection
  • Providing proof of concept for a role for pGC-A activators in cardiometabolic disease – how preclinical investigations of pGC-A demonstrate pleotropic actions on multiple organ systems and cell types
  • Understanding why ZD 100 represents a best in the class of pGC-A activating peptides
  • Presenting the results from the first in-human study

12.00 Lunch & Networking

13.00 Panel Discussion: Key Takeaways to Tackle the Future of Cardiovascular Drug Development – Are Cardiometabolics, Cardiorenal & Dyslipidaemia Approaches the Way to Go?

  • Gregory SchwartzM.D., Ph.D, Professor of Medicine (Cardiology), University of Colorado, Denver
  • Jay EdelbergM.D., Ph.D, VP & Head, Cardiovascular Development, Sanofi
  • John C. Burnett JrM.D., Marriott Family Professor of Cardiovascular Research, Division Of Cardiovascular Diseases, Mayo Clinic
  • Mark C. KowalaPh.D, CSO, CardioMetabolic and Diabetic Complications Drug Hunting Team, Eli Lilly and Company
  • Matthew T. RoeM.D., MHS, FACC, Professor of Medicine, Division of Cardiology, Duke University Medical Center, , Faculty Director, Global Outcomes Commercial Mega Trials, Duke Clinical Research Institute (DCRI)

Synopsis

  • Evaluating what these pharmacotherapeutic intersections mean for the development of future targets for cardiovascular therapeutics
  • Discussing drug safety and regulatory approval in this space
  • Assessing the response of payers, patients and practitioners
  • Outlining where we are and where we are going – important learnings to date and perspective on future directions

 

Therapeutic Developments in the Treatment of Heart Failure

13.45 Breakthroughs in Heart Failure Treatment – Single-Dose Treatments

Synopsis

  • Sharing Renova Therapeutics’ transformational therapy developments for congestive heart failure and acute decompensated heart failure
    • RT-100: AC6 gene therapy
    • RT-400: Stresscopin peptide infusion
  • Understanding single-dose treatment for heart failure – Renova’s second-generation gene therapy products

14.15 The Role of sGC Stimulators in the Treatment of Heart Failure

  • Joerg KoglinM.D., Ph.D, Associate VP, Section Head, Cardiovascular Clinical Research, Merck

Synopsis

  • Understanding the rationale and science behind soluble guanylate cyclase stimulation
  • Dosing finding and go-to-Phase-3 for Vericiguat
  • Looking into the Phase 3 approach in VICTORIA

14.45 Afternoon Refreshments & Networking

15.15 Targeting Mitochondria to Improve Outcomes in Heart Failure

  • Jim CarrVP, Clinical Development, Stealth BioTherapeutics

Synopsis

  • Evaluating the role of mitochondria in heart failure
  • Targeting end organ dysfunction in HF patients
  • Assessing clinical development concepts in targeting mitochondria

15.45 Pioneering Precision Cardiovascular Medicine

  • Eric GreenM.D., Ph.D, Head of Translational Research, MyoKardia, Inc.

Synopsis

  • Developing an integrated genotype/phenotype precision medicine platform for cardiovascular disease
  • Overviewing the first investigational drug discovered with this platform, MYK-461, currently in phase 2 studies for patients with symptomatic obstructive hypertrophic cardiomyopathy
  • Exploring a  second investigational drug, MYK-491, being developed for patients with dilated cardiomyopathy, which will be initiating clinical trials in 2017

16.15 Panel Discussion: What’s Next in the Treatment of Heart Failure?

  • Curtis RambaranM.D., FAHA, FRCP, Head of Cardiovascular Translational Medicine, Daiichi-Sankyo
  • Jack W. ReichPh.D, CEO & Co-Founder, Renova Therapeutics
  • Jim CarrVP, Clinical Development, Stealth BioTherapeutics
  • Joerg KoglinM.D., Ph.D, Associate VP, Section Head, Cardiovascular Clinical Research, Merck
  • Thomas PovsicM.D., Ph.D, Associate Professor of Medicine, Interventional Cardiologist, Duke Clinical Research Institute (DCRI)

Synopsis

  • Exploring novel thinking and the latest approaches to therapeutics in the treatment of heart failure
  • Discussing therapeutics safety and regulatory approval in this space
  • Analyzing the next steps in developing an increasingly efficient treatment to heart failure

17.00 Co-Chairs’ Closing Remarks

  • Kenneth W. MahaffeyM.D., Professor of Medicine; Vice Chair of Clinical Research; Director, Stanford Center for Clinical Research (SCCR), Stanford University
  • Scott M. WassermanM.D., FACC, VP, Global Development, Cardiovascular & Metabolic Therapeutic Area Head, Head of Development Design Center, Amgen Inc.

17.15 Close of Conference Day One


Wednesday, March 1, 2017
Day Two

 

08.00 Co-Chairs’ Opening Remarks

  • Kenneth W. MahaffeyM.D., Professor of Medicine; Vice Chair of Clinical Research; Director, Stanford Center for Clinical Research (SCCR), Stanford University
  • Scott M. WassermanM.D., FACC, VP, Global Development, Cardiovascular & Metabolic Therapeutic Area Head, Head of Development Design Center, Amgen Inc.

Synopsis

  • Key takeaways & lessons learned from day one
  • The future of cardiovascular research and drug development

Innovative Therapeutic Approaches & Technologies Against Cardiovascular Disease

08.15 Update on the New Developments in the Epigenetic Approach to Treating Cardiovascular Disease

  • Rusty MontgomeryPh.D, Associate Director, Research, miRagen Therapeutics, Inc.

Synopsis

  • An overview of the miRagen cardiovascular portfolio
    • New miRNA-based therapeutics and corresponding mechanisms of action in heart failure and hypertrophic cardiomyopathy
  • Cardiopulmonary miRNA-29 mimicking for cardiac fibrosis

08.45 Cardiovascular Hypoxia & Experimental Therapeutics

Synopsis

  • Understanding the pathophysiology of the vascular endothelial response to hypoxia
  • Exploring therapeutic options involving HIF and novel pathways
  • Introducing Coeurative, Inc. – creating curative strategies for cardiovascular diseases related to cellular hypoxia

09.15 BiowireTM II Platform for the Maturation of Human Engineered Cardiac Tissue for Drug Development, Drug Toxicity and Disease Modeling

  • Rooz SobbiPh.D., Senior Research Scientist, TARA Biosystems Inc.

Synopsis

  • The Biowire II platform is a human cardiac 3D tissue array designed to be the next generation in-vitro cardiac screen.
  • Biowire II tissues generated from human induced pluripotent stem cell-derived cardiomyocytes recapitulate many of the physiological hallmarks of the adult human myocardium, including a positive force-frequency relationship, post-rest potentiation, and non-spontaneous contraction.
  • The Biowire II platform allows for non-destructive and direct measurements of contractile force, simultaneous contractile force and Ca2+ transients measurements, and detailed action potential readouts.
  • The BiowireTM II platform is cell source agnostic and conducive to modeling monogenic and idiopathic cardiac diseases, enabling more relevant and predictive drug discovery and toxicity studies.

09.25 Developments in Myosin Activators for the Treatment of Heart Failure

  • Fady I. MalikM.D., Ph.D, Executive VP, Research & Development, Cytokinetics

Synopsis

  • Understanding the therapeutic rationale for cardiac myosin activation in heart failure
  • Discovering omecamtiv mecarbil
  • Exploring the results from the Phase 2 trial, COSMIC-HF
  • Analyzing the rationale and design of the Phase 3 cardiovascular outcomes study, GALACTIC-HF

09.55 Morning Refreshments & Networking

10.25 Patient Specific Stem Cells for Precision Cardiovascular Medicine

  • Joseph C. WuM.D., Ph.D, Director, Stanford Cardiovascular Institute, Professor of Medicine , (Cardiology) and Radiology, Stanford School of Medicine

Synopsis

  • Understanding how human induced pluripotent stem cells (iPSCs) are generated
  • Exploring how disease-specific iPSCs can be used to elucidate cardiovascular disease mechanisms
  • Discussing how patient-specific iPSCs can be used for precision cardiovascular medicine
  • Understanding how diverse panel of disease- and patient-specific iPSCs can be used for clinical trial in a dish

10.55 Hurdles to Bringing Novel Therapies to the Bedside: The example of Auto-CD34+ Cells

  • Thomas PovsicM.D., Ph.D, Associate Professor of Medicine, Interventional Cardiologist, Duke Clinical Research Institute (DCRI)

Synopsis

  • Understanding why regenerative therapy for heart disease may be a particularly attractive approach
  • Exploring key studies which have defined the use of this therapy for refractory angina and heart failure
  • Analyzing the key limitations to these studies and our understanding of regenerative approaches to CV disease
  • Understanding the hurdles to the development of regenerative and biological approaches to the treatment of CV disease

Precision Medicine Approaches to CV Research & CV Clinical Trial Innovation

11.25 Precision Cardiovascular Medicine at the American Heart Association

  • Prad PrasoonBusiness Technology Strategist, Institute for Precision Cardiovascular Medicine, American Heart Association

Synopsis

  • Understanding what can be achieve from the Precision Medicine Initiative in cardiovascular research
  • Putting patients at the center – speeding up research and discovery of new therapies for cardiovascular diseases and stroke by sharing health data
  • Exploring the Precision Cardiovascular Medicine Platform – a cloud-based data discovery portal to accelerate cardiovascular research

11.55 Precision Health: Innovative Approaches

  • Kenneth W. MahaffeyM.D., Professor of Medicine; Vice Chair of Clinical Research; Director, Stanford Center for Clinical Research (SCCR), Stanford University

Synopsis

  • Understanding the key molecular markers and what changes in these biomarkers may lead to disease
  • Providing insight on heart disease
  • Pointing out to new methods for early illness detection

12.25 Lunch & Networking

13.25 Beyond Causality: Resolving the Discordance Between Mendelian Randomization Studies & Recent Cardiovascular Outcome Trials

  • Brian A. FerenceM.D., MPhil, MSc, FACC, Associate Professor of Medicine; Clinical Chief, Division of Cardiovascular Medicine & Director, Cardiovascular Genomic Research Center, Wayne State University

Synopsis

  • Accelerating drug discovery and development – understanding that demonstrating causality is only the first step in genetic target validation
  • Moving beyond causality – anticipating the efficacy and safety of therapeutics by designing naturally randomized trials
  • De-risking the proposition – helping regulators understand how naturally randomized genetic evidence can be used to inform the design of randomized trials and as the basis for early therapy approval

 

13.55 ADAPTABLE, the Aspirin Study – A Patient-Centered Trial

  • Matthew T. RoeM.D., MHS, FACC, Professor of Medicine, Division of Cardiology, Duke University Medical Center, , Faculty Director, Global Outcomes Commercial Mega Trials, Duke Clinical Research Institute (DCRI)

Synopsis

  • Highlighting the electronic methods that are being used to facilitate the conduct of the ADAPTABLE trial
  • Describing the strong partnership with patients with cardiovascular disease that underlies the ADAPTABLE trial
  • Discussing the lessons learned from ADAPTABLE for the conduct of pragmatic cardiovascular trials

14.25 Panel Discussion: Potential for Digital Health Technologies to Transform Cardiovascular Trials & Post Marketing Surveillance

  • Helina KassahunM.D., FACC, Senior Medical Scientist in Global Development, Amgen Inc.
  • Matthew T. RoeM.D., MHS, FACC, Professor of Medicine, Division of Cardiology, Duke University Medical Center, , Faculty Director, Global Outcomes Commercial Mega Trials, Duke Clinical Research Institute (DCRI)
  • Mintu P. TurakhiaM.D. MAS, Assistant Professor, Senior Director of Research & Innovation, Center for Digital Health, Stanford University School of Medicine
  • Eric GreenM.D., Ph.D, Head of Translational Research, MyoKardia, Inc.

Synopsis

  • Streamlining clinical trial conduct with digital technology – current opportunities
  • Defining digital health endpoints
  • Exploring the barriers/challenges to utilizing digital technology in global CV clinical trials

15.15 Afternoon Refreshments & Networking

15.45 Panel Discussion: Addressing the Cost & Complexity of Cardiovascular Trials – An Overview of the Current Challenges & Opportunities in Trial Methodology

  • Brian A. FerenceM.D., MPhil, MSc, FACC, Associate Professor of Medicine; Clinical Chief, Division of Cardiovascular Medicine & Director, Cardiovascular Genomic Research Center, Wayne State University
  • Fady I. MalikM.D., Ph.D, Executive VP, Research & Development, Cytokinetics
  • Matthew T. RoeM.D., MHS, FACC, Professor of Medicine, Division of Cardiology, Duke University Medical Center, , Faculty Director, Global Outcomes Commercial Mega Trials, Duke Clinical Research Institute (DCRI)
  • Thomas PovsicM.D., Ph.D, Associate Professor of Medicine, Interventional Cardiologist, Duke Clinical Research Institute (DCRI)

Synopsis

  • Discussing the future of cardiovascular drug development – dead or alive?
  • Dealing with the regulatory burden – how time and cost drastically causes the need for cheaper, more efficient clinical trials
  • Exploring forward looking approaches to improving cardiovascular trials and outcomes:
    • Assessing streamlined and new approaches to outcome studies design
    • Evaluating safety of approach vs. efficacy in cardiovascular research
    • Is proof of hypothesis enough to understand broadness of applicability?
    • Extracting meaningful insight from big data sets to enhance trial outcomes and accelerate drug development
  • Tackling the approval challenges for novel therapies

16.45 Co-Chairs’ Closing Remarks

  • Kenneth W. MahaffeyM.D., Professor of Medicine; Vice Chair of Clinical Research; Director, Stanford Center for Clinical Research (SCCR), Stanford University
  • Scott M. WassermanM.D., FACC, VP, Global Development, Cardiovascular & Metabolic Therapeutic Area Head, Head of Development Design Center, Amgen Inc.

16.55 Close of Conference Day Two


 


Speaker Details


Brian A. Ference 
M.D., MPhil, MSc, FACC, Associate Professor of Medicine; Clinical Chief, Division of Cardiovascular Medicine & Director, Cardiovascular Genomic Research Center 
Wayne State University

 


Curtis Rambaran 
M.D., FAHA, FRCP, Head of Cardiovascular Translational Medicine 
Daiichi-Sankyo

 


Eric Green 
M.D., Ph.D, Head of Translational Research 
MyoKardia, Inc.

 


Fady I. Malik 
M.D., Ph.D, Executive VP, Research & Development 
Cytokinetics

 


Gregory Schwartz 
M.D., Ph.D, Professor of Medicine (Cardiology) 
University of Colorado, Denver

 


Helina Kassahun 
M.D., FACC, Senior Medical Scientist in Global Development 
Amgen Inc.

 


Jack W. Reich 
Ph.D, CEO & Co-Founder 
Renova Therapeutics

 


Jay Edelberg 
M.D., Ph.D, VP & Head, Cardiovascular Development 
Sanofi

 


Jim Carr 
VP, Clinical Development 
Stealth BioTherapeutics

 


Joerg Koglin 
M.D., Ph.D, Associate VP, Section Head, Cardiovascular Clinical Research 
Merck

 


John C. Burnett Jr 
M.D., Marriott Family Professor of Cardiovascular Research 
Division Of Cardiovascular Diseases, Mayo Clinic

 


John F. Schmedtje Jr. 
M.D., MPH, Founder, Coeurative, Inc.; Director 
Roanoke Heart Institute

 


Joseph C. Wu 
M.D., Ph.D, Director, Stanford Cardiovascular Institute, Professor of Medicine 
(Cardiology) and Radiology, Stanford School of Medicine

 


Kenneth W. Mahaffey 
M.D., Professor of Medicine; Vice Chair of Clinical Research; Director 
Stanford Center for Clinical Research (SCCR), Stanford University

 


Mark C. Kowala 
Ph.D, CSO, CardioMetabolic and Diabetic Complications Drug Hunting Team 
Eli Lilly and Company

 


Matthew T. Roe 
M.D., MHS, FACC, Professor of Medicine, Division of Cardiology, Duke University Medical Center, 
Faculty Director, Global Outcomes Commercial Mega Trials, Duke Clinical Research Institute (DCRI)

 


Mintu P. Turakhia 
M.D. MAS, Assistant Professor, Senior Director of Research & Innovation, Center for Digital Health 
Stanford University School of Medicine

 


Prad Prasoon 
Business Technology Strategist, Institute for Precision Cardiovascular Medicine 
American Heart Association

 


Rooz Sobbi 
Ph.D., Senior Research Scientist 
TARA Biosystems Inc.

 


Rusty Montgomery 
Ph.D, Associate Director, Research 
miRagen Therapeutics, Inc.

 


Scott M. Wasserman 
M.D., FACC, VP, Global Development, Cardiovascular & Metabolic Therapeutic Area Head, Head of Development Design Center 
Amgen Inc.

 


Thomas Povsic 
M.D., Ph.D, Associate Professor of Medicine, Interventional Cardiologist 
Duke Clinical Research Institute (DCRI)


Event Categories
Keywords: Clinical , development , industry , pharmaceutical , research , academics , Achieve, Challenge , challenges , clinic




Comments








Events Calendar

SunMonTueWedThuFriSat
29 30 31 1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 1 2 3 4

Event Location

Newsletters

Subscribe
VIP Life Time Subscription to our Newsletters!
$399.99
$299.99